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Angioimmunoblastic T-cell lymphoma (AIL) is a rare T-
cell malignancy with characteristic clinical and morpho-
logical features (1–3). Although it was originally thought
to be a relatively benign disorder and was classified as a
low-grade lymphoma, it is currently classified by the
WHO as a discrete entity representing around 20% of
aggressive T-cell lymphomas. This lymphoma mainly
affects elderly people who present an array of character-
istic signs and symptoms including disseminated lympha-
denopathy, constitutional symptoms, as well as known
haematological abnormalities (4).
No standard treatment for this aggressive disease has
yet been defined, in part due to the relative rarity of the
disease. Given the typical relationship of this lymphoma
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with autoimmune phenomena, immunomodulators such
as interferon (5–7) or other immunosuppressor drugs
such as cyclosporine (8, 9) and corticoids (10, 11) have
been reported to be active against the disease in simple
case reports or in very small series. Indeed, the vast
majority of reports dealing with this condition are simple
case reports treated with single agents or conventional
chemotherapy regimes typically used against aggressive
lymphomas. However, taking into account the dismal
prognosis of the disease, conventional chemotherapy
regimes have been tested, generally with unsatisfactory
results (11–18).
Following initial reports of the favourable impact of
high dose chemotherapy/autologous stem cell therapy
(HDC/ASCT), the European Group for Bone Marrow
Transplantation (EBMT) reported a 5-yr event-free sur-
vival (EFS) of 37% and an overall survival (OS) of 44%
at 5 yr in 29 patients, of whom 14 underwent transplan-
tation as a first line therapy (19). As a further contribu-
tion to redress the lack of data regarding therapeutic
measures for this condition, we report here our experien-
ces with 19 patients treated with HDC/ASCT within the
GELTAMO Spanish lymphoma group.
Patients and methods
Patients
Between 1992 and 2004, 19 patients with AIL who under-
went HDC/ASCT were reported to the GELTAMO
registry. The clinical characteristics of the patients at
diagnosis are shown in Table 1. The median age at trans-
plantation was 46 yr, and 15 patients were transplanted
as front line therapy having been judged by their primary
physician to have high risk factors of failure. Of these 15
patients, eight were transplanted as a consolidation of the
first complete response (CR), five patients were transplan-
ted in the first partial response (PR), and two patients
were transplanted in a primary refractory disease state.
Four patients received the transplant as a salvage ther-
apy, of which three patients were in a second or third CR
phase and one patient in the second PR (Table 2).
Standard criteria to determine eligibility for therapy
were applied including: bilirubin levels <2 mg/dL; creati-
nine levels <1.5 mg/dL; an ejection fraction >50%; and
appropriate diffusing lung tests >50% of the predictive
value. Histological diagnosis was established by the
pathologist in each centre. Cases that displayed difficult
diagnostic features were referred to an expert haemato-
pathologist following the recommendations of the group.
The disease stage was evaluated according to the Ann
Arbour staging system and patients were staged accord-
ing to standard procedures through: physical examina-
tion; blood and serum assays; chest X-rays; and
computed tomography of the neck, chest, abdomen and
pelvis. Bone marrow aspirates and biopsies were obtained
prior to HDC and other staging criteria were assessed at
Table 1 Clinical characteristics of patients at diagnosis and transplant
Variable At diagnosis At transplant
Age, mean (range) 46 (16–65)
Sex (M/F) 10 (53)/9 (47)
Ann Arbour Stage III–IV 16 (84) 4 (21)
B-symptoms 14 (74) 1 (5)
>1 extranodal sites 3 (16) 0 (0)
BM involvement 5 (26) 3 (16)
Bulky disease 3 (16) 0 (0)
ECOG PS >1 10 (53) 2 (10)
High LDH 10 (53) 4 (21)
High b2M 7 (50) 6 (43)
Age-adjusted-IPI 2–3 12 (63) 2 (10)
Tumour score 3–5 10 (56) 2 (12)
PPS 2–3 – 5 (38)
PIT >1 11 (61) 3 (17)
Pretransplant regimes
CHOP 9 (47)
MegaCHOP 7 (37)
MACOP-B 2 (10)
PromaceCytabon 1 (5)
Treatment lines pretransplant
First-line 15 (79)
Second-line 2 (10)
Third-line 2 (10)
BM, bone marrow; ECOG PS, Eastern Cooperative Oncology Group
Performance Status; LDH, lactate dehydrogenase; b2M, beta-2-micro-
globuline; IPI, International Prognostic Index; PPS, Pretransplant
Peripheral T-cell lymphoma Score; PIT, Prognostic Index for peripheral
T-cell lymphoma.
Values in parenthesis are in percentage.
Table 2 Transplant-related factors
Median months to transplant (range) 9 (4–51)
Disease status
First CR 8 (42)
Second or more CR 3 (16)
First PR 5 (26)
Second or more PR 1 (5)
Refractory 2 (10)
Conditioning regimens
BEAM 12 (63)
BEAC 3 (16)
Cy plus TBI 2 (10)
CVB 2 (10)
Stem cell source
BM 1 (5)
PB 18 (95)
Median apheresis (range) 3 (1–6)
Treatment-related mortality 0 (0)
Engraftment 19 (100)
CR, complete response; PR, partial response; BM, bone marrow; PB,
peripheral blood.
Values in parenthesis are in percentage.
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diagnosis to define the pretransplantation condition.
Standard variables of the age-adjusted International
Prognostic Index (a-IPI) (20) and other variables of
known prognostic importance in this type of lymphomas
were also evaluated (21–23). The details and factors asso-
ciated with transplantation are provided in Table 2.
Response and follow-up criteria
The response to therapy was evaluated by the investi-
gator responsible in each centre at 1, 3 and 6 months
post-transplantation, and every 6 months thereafter.
Evaluations followed standard guidelines (24), carrying
out a physical examination, complete blood counts,
serum biochemistry, bone marrow aspiration and biopsy,
and radiological studies as mentioned above. CR was
defined as the disappearance of all clinical evidence of
lymphoma for a minimum of 4 wk with no persistence of
symptoms related to the disease. Prior to transplantation,
a complete restaging was established in all patients. To
categorize a patient with a CR after HDC/ASCT, resid-
ual masses had to remain unchanged for 6 months or
longer. A PR was defined as a decrease of more than
50% in the sum of the two longest diameters of all meas-
urable lesions over at least 4 wk and non-measurable
lesions had to decrease by at least 50%. In this category,
no lesions increased in size and no new lesions appeared.
Progressive disease (PD) was defined as any increase of
more than 25% in the sum of the diameter of any meas-
urable lesions or the appearance of a new lesion. Trans-
plant-related mortality (TRM) was defined as death
within 100 d of HDC/ASCT not related to the disease,
relapse or progression. Toxic mortality was considered at
any time, if it was related to the therapeutic procedure.
Statistical methods
Progression-free survival (PFS) and OS were measured
from the date of transplantation and were estimated
according to the Kaplan–Meier method (25). Compari-
sons amongst the variables of interest were performed by
the log-rank test (26). All P-values reported were two-
sided and the statistical significance was defined at a
P-value < 0.05.
Results
Outcome
Post-transplantation, 79% of the whole population could
be considered to have achieved a CR (n ¼ 15), while 5%
of patients displayed a PR (n ¼ 1) and the procedure
failed in 16% (n ¼ 3, including the two cases transplan-
ted in a refractory disease state). Table 3 shows response
to transplant considering the disease status before trans-
plant. With a median observation time in living patients
of 25 months (9–151), the OS at 3 yr was 60% (95% CI:
37–83) and the PFS was 55% (95%, CI: 31–79; Fig. 1).
To date, eight patients had died, seven of them due to
the disease and one patient from a second neoplasia
(MDS). There were no incidences of TRM or toxic
deaths related to procedure.
Prognostic factors
Despite being a small group of patients, we performed a
univariate analysis to determine which clinical factors
Table 3 Response to transplant
Disease status at transplant
Response to transplant
CR PR Refractory
First CR 8 (100) 0 0
Second or more CR 3 (100) 0 0
First PR 4 (80) 0 1 (20)
Second or more PR 0 1 (100) 0
Refractory 0 0 2 (100)
CR, complete response; PR, partial response.
Values in parenthesis are in percentage.
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Figure 1 Overall survival and progression-free survival.
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might be associated with the outcome. The group of
eight patients transplanted in the first CR had an OS
and PFS at 3 yr of 56%. Similarly, no differences were
observed in the OS or PFS at 3 yr amongst the group of
15 patients transplanted as a front line therapy when
compared with the four patients who were transplanted
at relapse (67% vs. 50%, P ¼ 0.29 and 59% vs. 50%,
P ¼ 0.57 respectively). However, the refractory disease
state at transplantation that was observed in two
patients, predicted a dismal prognosis as both these
patients died from the disease shortly after the procedure
(within 1 and 3 months). Likewise, patients with extra-
nodal disease at the time of transplantation and with
bone marrow involvement were associated with a poor
outcome. Between the prognostic indexes studied the
outcome was significantly associated with the a-IPI, Pre-
transplant Peripheral T-cell lymphoma Score (PPS) (23)
and Prognostic Index for peripheral T-cell lymphoma
(PIT) (22) (Table 4, Fig. 2).
Discussion
AIL is a rare disease with a poor prognosis. With the
therapeutic strategies currently available, a median survi-
val of 18–36 months has been observed when conven-
tional chemotherapy was applied in most series (4, 12).
There is a lack of informative series of patients that have
been treated uniformly and indeed, most reports include
single patients or very small groups of patients. There-
fore, it is difficult to draw firm conclusions from the
information obtained to date. Recently, the EBMT
reported their experiences with 29 patients diagnosed
with this disease and subjected to HDC/ASCT. Half of
the patients received the transplant as part of a first-line
therapy and half as second or third line therapy (19).
This group reported a CR of 76% after HDC/ASCT,
which is similar to the CR in our series (79%). Along
similar lines, the 5-yr OS and PFS were 44% and 37%
respectively, inferior to our 60% and 55% OS and PFS
at 3–5 yr respectively. However, this may reflect the fact
that most of our patients (79%) were transplanted as a
first line treatment as opposed to 45% in the EBMT ser-
ies. Furthermore, our median observation period of
25 months for surviving patients is shorter than the
60 months in the EBMT series.
Our analysis showed that like patients with other
aggressive Peripheral T-cell lymphoma (PTCL), those
transplanted in a refractory disease state do poorly with
HDC/ASCT (27–29). In addition, we found that the
presence of extranodal disease (bone marrow) or more
than one adverse factor at transplant of those assessed in
the a-IPI, PPS or PIT scores was associated with a worse
outcome. Although studied in few patients, this informa-
tion suggests that HDC/ASCT improves the outcome of
the disease when compared with conventional treatment,
indicating that prospective studies to test this therapeutic
modality are necessary. Moreover, the use of this therapy
is limited in the elderly population. Therefore, taking
into account the biological phenomena associated with
Table 4 Prognostic factors at transplant
Parameter
OS at 3 yr, %
(95% CI) P-value
PFS at 3 yr, %
(95% CI) P-value
Status at transplant
CR 65 (31–99) <0.001 65 (31–99) 0.011
PR 67 (29–100) 50 (10–90)
Refractory disease 0 0
Extranodal disease
No 69 (44–95) 0.049 62 (35–89) NS
Yes 25 (0–67) 25 (0–67)
BM involvement
No 72 (48–96) <0.001 65 (40–91) <0.001
Yes 0 0
Age-adjusted-IPI
0 or 1 68 (44–92) <0.001 61 (36–86) 0.005
More than 1 0 0
PPS
0 75 (45–100) 0.001 62 (29–95) NS
1 50 (1–99) 50 (1–99)
2 0 0
PIT
0 or 1 64 (38–90) 0.019 57 (30–84) NS
More than 1 33 (0–86) 33 (0–86)
Tumour score
0–2 65 (39–91) NS 57 (21–84) NS
3–5 50 (0–100) 50 (0–100)
Age >60 yr
No 62 (38–86) NS 56 (31–80) NS
Yes 67 (13–100) 67 (13–100)
Ann Arbour Stage
No disease — NS 65 (31–99) NS
I-II 75 (33–100) 50 (1–99)
III-IV 25 (0–67) 25 (0–67)
ECOG PS >1
No 61 (36–86) NS 55 (29–81) NS
Yes 50 (0–100) 50 (0–100)
High LDH
No 61 (33–88) NS 53 (24–81) NS
Yes 50 (1–99) 50 (1–99)
High b2M
No 75 (45–100) NS 62 (19–96) NS
Yes 44 (1–88) 44 (1–88)
Induction regime
CHOP 65 (32–97) NS 67 (36–97) NS
MegaCHOP 54 (14–93) 54 (14–93)
OS, overall survival; PFS, progression-free survival; CI, confidence
interval; CR, complete response; PR, partial response; BM, bone mar-
row; IPI, International Prognostic Index; PPS, Pretransplant Peripheral
T-cell lymphoma Score; PIT, Prognostic Index for peripheral T-cell lym-
phoma; ECOG PS, Eastern Cooperative Oncology Group Performance
Status; LDH, lactate dehydrogenase; b2M, beta-2-microglobuline; NS,
not significant.
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the disease, novel more specific therapies will be needed
and other potential targets must be defined. Interestingly,
immunomodulatory and antiangiogenic agents have been
reported to have positive impact on the disease (IFNa,
IL-2, Thalidomide. . .), however the real impact of these
agents remains unknown due to the small number of
patients studied (4, 30).
Another intriguing approach that involves targeting
the B-cell component rather than the malignant T-cell
population is currently being tested (31). Indeed, this B-
cell component is responsible for several features of the
disease and it is argued that it may contribute to sustain
the malignant T cells. Along similar lines, there are sev-
eral reports outlining the responses to Rituximab in
treating this disease. Furthermore, a certain efficacy has
also been reported with Campath-1H in single case
reports (32). Thus, new biological agents, used either
individually or in combination with conventional chemo-
therapy may have an impact on the disease. However, as
suggested by our data and that of others ASCT, may
represent the best available consolidation therapy for
patients that comply with certain criteria.
In conclusion, our data show that HDC/ASCT offers
better results than conventional chemotherapy in treating
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Figure 2 Prognostic factors associated with overall survival. A) Significant adverse prognostic factors. B) Significant prognostic scores.
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aggressive lymphomas. Although further follow-up is
needed to confirm these results, more than half of the
patients in this study were in continued remission. How-
ever, we identified several factors such as refractory dis-
ease state, extranodal disease (bone marrow involvement)
and the presence of more than one adverse factor from
the a-IPI, PPS or PIT pretransplantation scores that are
unfavourable factors associated with a poor outcome of
this therapeutic modality. New target therapies drawn
from genomic and proteomic studies should be defined
in order to develop more specific therapies. Moreover,
due to the rarity of the disease, cooperative efforts and
well-designed prospective studies are needed in order to
reach meaningful conclusions.
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